Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In good health in the judgment of the Investigator as determined by medical history, physical examination, and screening laboratory assessments.~* Female of childbearing potential must have a negative result on the screening serum pregnancy test and must agree to practice contraception by a method of proven reliability (includes abstinence) for the duration of the study.~Exclusion Criteria:~* Pregnant or lactating females.~* Clinical evidence of any significant acute or chronic disease that may interfere with successful completion of the trial.~* Clinically significant history of the following: cardiovascular disease, hyperlipidemia, serious respiratory disease including bronchitis or asthma, endocrine disorder, liver disease, glaucoma, gastrointestinal disease, disorder of the reticuloendothelial system, or neurologic illness.~* History of angioedema or nephrotic syndrome.~* Non-controlled arterial hypertension.~* Anemia at screening.~* Significant proteinuria (\> 1 + on urine dipstick) and/or has a history of acute renal failure and/or severe renal impairment or a blood urea nitrogen or creatinine more than 2.5 times the upper limit of normal at screening and/or currently receiving dialysis.~* Elevated liver enzymes (aspartate transaminase, alanine aminotransferase) and Gamma-glutamyl Transferase) equal to or greater than 1.5 times the upper limit at screening.~* Previously received the rabies vaccine and/or rabies immune globulin.~* Received infusion of a blood/plasma product or fraction within the past 12 months, including any type of immune globulin.~* Known adverse reaction to administration of any immune globulin or other blood/plasma products.~* Experienced anaphylactic shock with the administration of blood/plasma products.~* Known medical history of selective immunoglobulin A (IgA) deficiency.~* Received any corticosteroids, immunosuppressants, or immunomodulators within 6 weeks prior to screening.~* Expects to receive oral or topical non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, antihypertensives, and/or antihistamines 24 hours before or after investigational product administration during the Baseline/Treatment, Study Day 0 visit.~* Currently receiving any anti-viral treatment.~* Screening laboratory results indicative of an acute or chronic infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or parvovirus B19 (B19V).~* Participated in another clinical trial within 30 days prior to screening (imaging studies without investigative treatments are permitted) or has received any investigational products within the previous 3 months.~* Not willing to postpone receiving any live virus vaccines until 3 months after receiving investigational product.~* History of a psychiatric illness requiring hospitalization.~* Known substance or prescription drug abuse in the past 12 months.~* Any active medical illness that the Investigator may consider a potential confounding condition that would interfere with the study visits and/or procedures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RIG-C (Type: EXPERIMENTAL): Single 20 IU/kg dose of RIG-C by intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete